Skip to main content

Savella FDA Approval History

FDA Approved: Yes (First approved January 14, 2009)
Brand name: Savella
Generic name: milnacipran
Company: Allergan plc
Treatment for: Fibromyalgia

Savella (milnacipran) is a selective serotonin and norepinephrine reuptake inhibitor indicated for the management of fibromyalgia.

Development timeline for Savella

DateArticle
Jan 15, 2009Approval Forest and Cypress Announce FDA Approval of Savella for the Management of Fibromyalgia
Oct 20, 2008FDA Defers Final Action on Milnacipran New Drug Application
Feb 21, 2008Forest and Cypress Announce FDA Acceptance for Review of New Drug Application for Milnacipran for the Treatment of Fibromyalgia
Jan  2, 2008Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome

See also

Savella (milnacipran) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer